IRAK1 Cancer Research Results

IRAK1, Interleukin-1 Receptor-Associated Kinase 1: Click to Expand ⟱
Source:
Type:

IRAK1 (Interleukin-1 Receptor-Associated Kinase 1) — Serine/threonine kinase and key signaling mediator downstream of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs). Following MyD88-dependent receptor activation, IRAK4 activates IRAK1, which interacts with TRAF6 and promotes downstream TAK1, IKK/NF-κB, MAPK/JNK/p38, and inflammatory transcriptional signaling.

Typical modulation in cancer: Frequently ↑ or hyperactivated and generally tumor-promoting. Elevated IRAK1 signaling can support proliferation, survival, cancer stemness, inflammatory tumor microenvironment, migration, metastasis, and resistance to therapy. IRAK1 inhibition or degradation is therefore being investigated as an anticancer strategy.

Typical modulation in Alzheimer’s disease: ↑ IRAK1 signaling may contribute to TLR/IL-1-driven microglial and astrocytic neuroinflammation. Experimental inhibition of IRAK1/IRAK4 signaling has been investigated as a means of reducing neuroinflammatory signaling relevant to Alzheimer’s disease.

Typical mechanistic relationship: TLR / IL-1R → MyD88 → IRAK4 → IRAK1 → TRAF6 → TAK1 → NF-κB and MAPK activation ↑ → inflammatory cytokine expression ↑.
Scientific Papers found: Click to Expand⟱
8845- DIM,  I3C,    3,3′-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways
- Review, Var, NA
*BioAv↝, *BioAv↓, *BioAv↓, *AntiAg↑, *ROS↓, *AntiThr↑, *Stroke↓, *CYP1A1↑, *CYP1A2↑, *GSTs↑, *NQO1↑, AntiTum↑, AntiCan↑, TumAuto↓, Let-7↑, miR-34a↑, TumCMig↓, Apoptosis↑, MMP↓, mtDam↑, ROS↑, TumCCA↑, other↝, PSA↓, Dose↝, MMP2↓, MMP3↓, MMP9↓, EGFR↓, RAS↓, PI3K↓, Akt↓, mTOR↓, CDK4↓, cycD1/CCND1↓, P21↑, MDM2↓, TumCP↓, NF-kB↓, RANKL↓, PUMA↓, Wnt↓, MTA2↓, EZH2↓, AhR↓, PTEN↑, NOTCH1↓, IRAK1↓, p27/CDKN1B↓, CDKN1C/p57↓, CDC25↓, EGFR↓, Zeb1↓, FOXM1↓, SOX4↓, E-cadherin↑, uPA↓, uPAR↓,
8851- DIM,    3,3’-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs
- Review, Var, NA
Apoptosis↑, NF-kB↓, Akt↓, Wnt↓, PI3K↓, mTOR↓, PSA↓, Let-7↓, miR-34a↓, EZH2↓, NOTCH1↓, AR↓, E-cadherin↑, Zeb1↓, Vim↓, Slug↓, EMT↓, MTA2↓, NF-kB↓, IRAK1↓, EGFR↓, SOX4↓, FOXM1↓, p27/CDKN1B↓, AhR↓, EZH2↓, Wnt↓, PUMA↓, AEG1↑, ROS↑, PPARα↑, CycB/CCNB1↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   mtDam↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 2,   MDM2↓, 1,   PUMA↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   EGFR↓, 3,   mTOR↓, 2,   PI3K↓, 2,   PTEN↑, 1,   RAS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 3,   FOXM1↓, 2,   miR-34a↓, 1,   miR-34a↑, 1,   MTA2↓, 2,   other↝, 1,   SOX4↓, 2,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CDKN1C/p57↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 1,   P21↑, 1,   p27/CDKN1B↓, 2,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Let-7↓, 1,   Let-7↑, 1,   NOTCH1↓, 2,   TumCP↓, 1,   Wnt↓, 3,  

Migration(tgid=13) ⓘ

AEG1↑, 1,   E-cadherin↑, 2,   EMT↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   Slug↓, 1,   TumCMig↓, 1,   uPA↓, 1,   uPAR↓, 1,   Vim↓, 1,   Zeb1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IRAK1↓, 2,   NF-kB↓, 3,   PSA↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AhR↓, 1,   AhR↓, 1,   AR↓, 1,   PPARα↑, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 3,   EZH2↓, 3,   FOXM1↓, 2,   PSA↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiTum↑, 1,  
Total Targets: 61

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSTs↑, 1,   NQO1↑, 1,   ROS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↝, 1,   CYP1A1↑, 1,   CYP1A2↑, 1,  

Functional Outcomes(tgid=23) ⓘ

Stroke↓, 1,  
Total Targets: 10

Scientific Paper Hit Count for: IRAK1, Interleukin-1 Receptor-Associated Kinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1896  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page